Abbott Laboratories (ABT) Stock Price & Analysis
Abbott Laboratories (ABT) rose 0.83% to USD 91.25 as of June 9, 2026 at 22:41 UTC, according to Nexqual real-time market data.
ABT last closed at USD 90.5; the session ranged USD 90.13–92.02 on volume of 11,884,719 shares. Market capitalization is $158.94B, with a 52-week range of USD 81.97–139.06 (NYQ). Source: Nexqual, June 9, 2026 at 22:41 UTC.
Key Statistics (as of June 9, 2026 at 22:41 UTC)
| Price | USD 91.25 |
|---|---|
| Change | ▲ 0.83% (up) |
| Previous Close | USD 90.5 |
| Open | USD 90.73 |
| Day Range | USD 90.13 – 92.02 |
| 52-Week Range | USD 81.97 – 139.06 |
| Volume | 11,884,719 shares |
| Market Cap | $158.94B |
| Exchange | NYQ |
Technical Analysis (ABT)
Nexqual's technical model rates ABT "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 22:41 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 58.19 (neutral) |
| vs SMA50 | Below (USD 92.01) |
| MACD | -0.29 (negative) |
Analyst Ratings (ABT)
Wall Street analysts rate ABT "Buy" based on 24 analysts, with a mean price target of USD 117.29 (range USD 92–135), per Nexqual as of June 9, 2026 at 22:41 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 24 |
| Mean Target | USD 117.29 |
| High Target | USD 135 |
| Low Target | USD 92 |
| Buy / Hold / Sell | 20 / 7 / 0 |
Earnings (ABT)
| Next Earnings Date | 2026-07-16 |
|---|---|
| EPS Estimate | USD 1.28 |
| Revenue Estimate | $12.53B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.15 vs est 1.15 ▲ beat |
| 2025-12-31 | USD 1.5 vs est 1.49 ▲ beat |
| 2025-09-30 | USD 1.3 vs est 1.3 ▲ beat |
| 2025-06-30 | USD 1.26 vs est 1.26 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:41 UTC.
Financials & Fundamentals (ABT)
| Total Revenue | $45.13B |
|---|---|
| Revenue Growth (YoY) | +7.80% |
| Gross Margin | +56.50% |
| Operating Margin | +13.47% |
| Profit Margin | +13.90% |
| ROE | +12.33% |
| Debt / Equity | 64.77 |
| Current Ratio | 1.39 |
| Total Cash | $7.30B |
| Total Debt | $34.14B |
| Free Cash Flow | $6.34B |
Source: Nexqual, June 9, 2026 at 22:41 UTC.
Financial Health Score (ABT)
Nexqual rates Abbott Laboratories's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:41 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 13% |
| Balance Sheet | Solid — $7.30B cash vs $34.1B debt |
| Cash Flow | Solid — FCF $6.34B, 14% margin |
| Efficiency | Mixed — ROE 12%, ROA 5.6% |
Ownership (ABT)
| Insider Ownership | +0.50% |
|---|---|
| Institutional Ownership | +82.69% |
| Shares Outstanding | 1.74B |
| Float | 1.73B |
| Short % of Float | +1.49% |
Source: Nexqual, June 9, 2026 at 22:41 UTC.
Leadership (ABT)
Abbott Laboratories is led by Robert B. Ford (age 51), Chairman, President & CEO, per Nexqual as of June 9, 2026 at 22:41 UTC.
| Chairman, President & CEO | Robert B. Ford (age 51) |
|---|---|
| CFO & Executive VP of Finance | Philip P. Boudreau (age 52) |
| Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | Daniel Gesua Sive Salvadori (age 46) |
| Executive Vice President of Diabetes Care | Christopher J. Scoggins (age 55) |
| Executive VP & Group President of Medical Devices | Lisa D. Earnhardt (age 55) |
Major Backers & Investors (ABT)
Notable institutional backers of Abbott Laboratories include Capital Group, Charles Schwab Investment Management, Inc., Capital International Investors, according to Nexqual as of June 9, 2026 at 22:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 2.86% |
| Charles Schwab Investment Management, Inc. | 2.61% |
| Capital International Investors | 2.15% |
| Morgan Stanley | 1.73% |
| Wellington Management | 1.55% |
| Fidelity | 1.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.86% |
| BlackRock | 9.65% |
| State Street | 5.76% |
| Geode Capital | 2.25% |
Source: Nexqual, June 9, 2026 at 22:41 UTC.
From Abbott Laboratories's Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services has issued rules governing the use, disclosure, and security of protected health information, and the FDA has issued further guidance concerning cybersecurity for medical devices.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABBV | AbbVie Inc. | USD 225.42 | ▼ 0.8% |
| BMY | Bristol-Myers Squibb Company | USD 56.48 | ▼ 1.38% |
| JNJ | Johnson & Johnson | USD 237 | ▲ 1.82% |
| MDT | Medtronic plc. | USD 81.98 | ▲ 0.38% |
| LLY | Eli Lilly and Company | USD 1,144.68 | ▲ 1.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:41 UTC. This page is informational and not investment advice.